{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 8 of 129', 'Section no. and', 'Description of change', 'Brief rationale', 'name', 'Section 12.3.9.5', 'Evaluations of nAB will be conducted', 'To reflect that titre information from', 'Anti-drug', 'on those serum samples that test', 'the nAB assay will not be available.', 'antibodies', 'positive for ADA. The test sample is', 'deemed positive or negative for the', 'presence of nAB to tralokinumab', 'relative to a pre-determined (in assay', 'validation) statistically derived cut', 'point. Samples positive for nAB to', 'tralokinumab are then titrated to', 'determine relative amounts of nAB', 'present in each test sample.', 'Appendix 6', 'LEO Pharma protocol authors are', 'To comply with the European', 'Contact list', 'omitted.', 'General Data Protection Regulation.', 'Throughout', 'Minor editorial and document', 'Minor, have therefore not been', 'formatting revisions.', 'summarised.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 9 of 129', 'Table of contents', 'Clinical trial protocol statements', '2', 'Protocol amendment summary of changes table', '3', 'Table of contents', '9', 'List of panels', '14', 'List of abbreviations', '15', '1 Protocol synopsis', '17', '2 Trial identification', '21', '3 Schematic of trial design', '21', '4 Schedule of procedures', '22', '5 Introduction and rationale', '26', '5.1 Atopic dermatitis', '26', '5.2 Experience with investigational medicinal product', '26', '5.3', 'Trial rationale', '27', '5.4', 'Justification for dose', '28', '5.5', 'Benefit/risk assessment', '29', '5.6 Ethical considerations', '30', '6 Trial objectives and endpoints', '32', '7 Trial design', '34', '7.1 Overall trial design', '34', '7.2 Number of subjects needed', '37', '7.3 End of trial definition', '37', '7.4 Scientific rationale for trial design', '37', '8 Trial population and withdrawal', '38', '8.1 Subject eligibility', '38', '8.2', 'Inclusion criteria', '39', '8.3', 'Exclusion criteria', '40', '8.4 Enrolment', '44', '8.5', 'Discontinuation', '44', '9 Treatments', '47', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 10 of 129', '9.1', 'Trial product description', '47', '9.1.1', 'Investigational medicinal product', '47', '9.1.2', 'Non-investigational medicinal product', '48', '9.1.3', 'Administration of trial products', '48', '9.1.3.1', 'Administration of IMP', '48', '9.1.3.2', 'Administration of NIMP', '50', '9.2', 'Treatment assignment', '50', '9.2.1', 'Blinding', '51', '9.2.2', 'Emergency unblinding of individual subject treatment', '52', '9.3', 'Background treatment (emollients)', '52', '9.4 Concomitant medication and procedures', '53', '9.5 Prohibited medication and procedures', '54', '9.6 Rescue treatment', '55', '9.7 Dose modification and IMP discontinuation rules', '55', '9.7.1', 'Reasons for permanent discontinuation of IMP', '55', '9.7.2', 'Reasons for temporary discontinuation of IMP', '56', '9.8', 'Treatment logistics and accountability', '57', '9.8.1', 'Labelling and packaging of trial products', '57', '9.8.1.1', 'Labelling and packaging of IMPs', '57', '9.8.1.2', 'Labelling and packaging of NIMP', '57', '9.8.2', 'Storage of trial products', '57', '9.8.2.1', 'Storage of IMPs', '57', '9.8.2.2', 'Storage of NIMP', '58', '9.8.3', 'Drug accountability', '59', '9.8.3.1', 'IMP accountability', '59', '9.8.3.2', 'NIMP accountability', '59', '9.8.4', 'Trial product destruction', '60', '9.8.5', 'Treatment compliance', '60', '9.9 Provision for subject care following trial completion', '60', '9.10 Reporting product complaints', '60', '10 Trial schedule and assessments', '62', '10.1 Overview', '62', '10.2 Assessments performed only at screening/baseline', '63', '10.2.1 Columbia-Suicide Severity Rating Scale', '63', '10.2.2 Demographics', '63', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}